Bond.az White LogoBond.az Black Logo

UBS Upgrades Vipshop on Earnings

UBS upgrades Vipshop stock to Buy, cuts target to $18.50. Vipshop trades at 6x P/E with strong cash position and 4.16% dividend yield.

David Wilson
ByDavid Wilson- Senior Editor
|
0

Bond.az – UBS upgraded Vipshop Holdings (NYSE:VIPS) to Buy from Neutral, while lowering its price target to $18.50 from $20.00.

Near-term growth is expected to remain pressured amid muted consumption and intense e-commerce competition. However, earnings resilience should be supported by strong first-party margin control and increasing contributions from Shanshan offline outlets.

Vipshop trades at 6 times 2026 estimated P/E, at the low end of its historical average. UBS believes the market has discounted most of the growth uncertainty.

Downside is cushioned with net cash at approximately 50% of market cap and approximately 14% committed shareholder returns. The current dividend yield stands at 4.16%. Even assuming a low single-digit EPS decline in 2026, this implies an approximately 10% total return.

Vipshop also reported Q1 2026 earnings, with EPS of 4.68 RMB surpassing forecasts. Revenue reached 26.6 billion RMB, slightly above expectations.

This article was generated with AI support and reviewed by an editor. For more information see our T&C.

More News
Today / 13:02
|
903

JPMorgan raises Fibra Uno price target on NEXT

JPMorgan raised Fibra Uno's price target to Peso36, citing NEXT consolidation and internalization. The stock offers a 9.61% dividend yield.

0
Today / 13:00
|
675

BofA Initiates Pershing Square Stock with Neutral Rating

BofA Securities starts Pershing Square with Neutral rating and $42 target. Analysis highlights unique fee structure and strong performance.

0
2026-05-22 14:25
|
910

Benchmark cuts Lightspeed stock price target

Benchmark cuts Lightspeed price target to $16, maintains Buy. LSPD shares trade at $8.57 with a market cap of $1.18B.

0
2026-05-22 14:23
|
696

Benchmark Reiterates NetEase Buy

Benchmark reiterates Buy on NetEase after strong Q1 results, citing AI integration and margin expansion.

0
2026-05-22 14:21
|
911

Benchmark Reaffirms Spotify Stock Rating

Benchmark reaffirms Buy rating on Spotify stock with $695 target, citing engagement monetization strategy. Spotifys financial health and Audiobooks Plus success highlighted.

0
2026-05-22 14:04
|
264

Keefe Bruyette Reiterates Progressive Stock Rating at Market Perform

Keefe, Bruyette & Woods reiterates Market Perform rating on Progressive stock with $208 price target.

0
2026-05-22 14:03
|
304

Datadog stock Buy rating reaffirmed

DA Davidson reaffirms Datadog Buy rating with $250 target, citing AI positioning and long-term growth.

0
2026-05-22 13:31
|
725

Generac Stock Upgrade: Data Center Outlook

Jefferies upgrades Generac stock to Buy, citing data center prospects. Target price raised to $302. Stock up 100% in a year.

0
2026-05-22 12:50
|
462

KeyBanc Reiterates Overweight on Walmart, $145 Target

KeyBanc reiterates Overweight on Walmart with $145 target. Walmart shows strong market share gains and digital momentum despite recent stock decline.

0
2026-05-22 12:23
|
531

Cantor Fitzgerald Reiterates Workday Rating on AI Growth

Cantor Fitzgerald reaffirms Workday Overweight rating, highlighting AI growth. Stock at $121.85, target $160.

0
2026-05-22 12:21
|
379

Cantor Reiterates Overweight on ORIC Stock

Cantor Fitzgerald reiterated Overweight on ORIC Pharmaceuticals. Pfizer trial results and analyst ratings update.

0
2026-05-22 12:20
|
278

Summit Therapeutics Analysis: Cantor Fitzgerald Backs Overweight

Cantor Fitzgerald reiterates Overweight on Summit Therapeutics. HARMONi-3 trial miss and analyst views covered by Bond.az.

0
...